Anti-CD40L Antibody Tegoprubart Outperforms Tacrolimus in Preserving Kidney Transplant Function

The transplant community has long accepted a difficult clinical compromise: the medications required to stop the body from rejecting a new kidney eventually damage the organ themselves. Calcineurin inhibitors like tacrolimus are highly effective at suppressing the immune system, making them the undisputed standard of care for transplant recipients. Yet their cumulative toxicity drives hypertension, diabetes, and a slow scarring of the graft that ultimately limits its lifespan.[1]

On the other side of this clinical divide are researchers pursuing targeted immunomodulation, arguing that broad immune suppression is a blunt instrument. They advocate for blocking specific communication pathways between immune cells, a strategy intended to induce tolerance without the collateral damage. Until recently, proving that this targeted approach could match the sheer efficacy of tacrolimus in preventing acute rejection remained a formidable hurdle.

That balance of evidence shifted this week at the American Society of Nephrology Kidney Week 2026 in Denver. Investigators presented long-term data from the Phase 2 BESTOW clinical trial, comparing the novel anti-CD40L antibody tegoprubart directly against tacrolimus in adults receiving their first kidney transplant. The results suggest the experimental therapy not only prevents rejection but actively preserves the organ's function better than the current standard.[1][4]

Measuring graft survival

Kidney function is primarily measured by the estimated glomerular filtration rate, or eGFR, which tracks how well the organ filters waste from the blood. In the BESTOW trial, graft function stabilized after the first month of treatment for patients receiving tegoprubart. By the 18-month mark, those patients maintained a statistically significant advantage in filtration rates compared to the tacrolimus control group.[1][2][3]

Specifically, the mean eGFR for the tegoprubart group sat at 74 mL/min/1.73 m², compared to 61 mL/min/1.73 m² for those on tacrolimus. This 13-point difference represents a substantial margin in clinical nephrology, indicating a healthier, more resilient graft. For a patient, maintaining a filtration rate in the seventies often means the difference between feeling energetic and experiencing the early fatigue of chronic kidney disease.

"Treatment today with tacrolimus helps prevent organ rejection but at a high cost to patients," noted Dr. Andrew Adams of the University of Minnesota Medical School, the study's corresponding author. He highlighted that the standard regimen frequently induces kidney toxicity, tremors, and cognitive issues commonly described as brain fog. The trial data indicates that avoiding these specific toxicities allows the transplanted organ to thrive.[1]

The mechanism behind tegoprubart explains this divergence in side effects. Rather than broadly dampening the immune system, the monoclonal antibody specifically targets the CD154, or CD40 ligand, pathway. This pathway is central to how T-cells activate and coordinate the immune responses that lead to organ rejection.[1]

Quality of life improvements

By interrupting this specific communication channel, tegoprubart prevents the immune system from attacking the foreign tissue while leaving other cellular functions largely intact. Because it avoids the calcineurin pathway entirely, it bypasses the metabolic and neurological side effects that make standard immunosuppression so difficult for patients to tolerate. This biological precision translated directly into how patients felt during the trial.

A separate analysis of the BESTOW data focused entirely on patient-reported outcomes, measuring health-related quality of life over the first year post-transplant. Of the 127 patients initially treated, 107 completed the study through week 52. Researchers used validated symptom scales to track the physical and psychological burden of the medications.[1][4]

Patients receiving tegoprubart reported improvements from their baseline across all five subscales of the kidney disease quality-of-life assessment. In contrast, the tacrolimus group saw improvements in only four of the five areas. More notably, the tegoprubart cohort demonstrated a significantly greater improvement on the mental component summary, reflecting a lower psychological burden.[1][3][4]

The overall symptom score for patients on the experimental drug declined numerically more than for those on the standard of care. This reduction in daily symptoms—fewer tremors, less fatigue, and better metabolic stability—provides a practical reassurance to patients facing a lifetime of immunosuppression. It suggests that preserving the graft does not have to come at the expense of daily well-being.[1][4]

The path to clinical practice

For current transplant recipients, these findings are highly encouraging, though they do not change immediate clinical practice. Tegoprubart remains an investigational therapy, and patients currently stable on tacrolimus should not alter their regimens. The transition from a successful Phase 2 trial to widespread clinical availability requires confirming these results in a larger, more diverse population.[5]

Eledon Pharmaceuticals, the developer of tegoprubart, has already established the regulatory framework for the next step. Following a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration, the company is preparing to launch the global Phase 3 LEGACY trial in late 2026. This pivotal study will enroll approximately 600 patients to definitively test non-inferiority against tacrolimus.[5]

The primary endpoint for the upcoming Phase 3 trial will evaluate a composite of biopsy-proven acute rejection, graft loss, and death at 52 weeks. If tegoprubart can match tacrolimus on these critical safety metrics while maintaining its advantage in kidney function and symptom reduction, it could fundamentally alter transplant protocols. The FDA has already granted Fast Track designation to the therapy, acknowledging the urgent need for less toxic alternatives.[5]

Beyond kidney transplantation, the success of CD40L inhibition could have broader implications for the field of immunology. Eledon is currently evaluating the drug's potential in islet cell transplantation for diabetes, liver transplantation, and even xenotransplantation. If the mechanism proves universally effective at inducing tolerance, it could become the new cornerstone of immunosuppression across multiple organ types.[5]

Redefining transplant success

Historically, the transplant community measured success almost entirely by one-year graft survival rates, a metric where tacrolimus excels. However, as surgical techniques have perfected those early outcomes, clinical focus has shifted toward the long-term durability of the organ. A kidney that survives the first year but slowly succumbs to medication-induced scarring often forces the patient back onto the transplant waitlist a decade later.

By preserving a higher glomerular filtration rate at 18 months, tegoprubart addresses this exact vulnerability. A graft that maintains robust filtration without accumulating toxic damage is theoretically positioned to last significantly longer. Extending the average lifespan of a transplanted kidney from the current ten years to fifteen or twenty would dramatically reduce the need for repeat transplants.[1]

This shift would alleviate immense pressure on the global organ shortage, making more kidneys available for first-time recipients and shortening wait times across the board. It represents a transition from merely preventing acute failure to actively managing the long-term health of both the organ and the recipient. The BESTOW trial data provides the strongest evidence yet that this transition is biologically possible.[1]

While the data is overwhelmingly positive, researchers are careful to flag the inherent uncertainties of a Phase 2 study. The trial cohort was relatively small, and 18 months of follow-up, while significant, does not capture the full decade-long lifecycle of a transplanted organ. Rare adverse events or late-stage rejection patterns may only become apparent when the drug is tested in thousands of patients over several years.[5]

The absence of any biopsy-proven acute rejection events in the tegoprubart arm after the first six months post-transplant offers a strong signal of durable efficacy. For a field that has relied on calcineurin inhibitors since the 1990s, a targeted antibody that preserves filtration rates without inducing tremors or diabetes represents a structural shift in care. The upcoming 600-patient LEGACY trial will provide the definitive statistical proof required to rewrite those standard protocols.[5]